Labcorp Holdings Inc. $LH Position Raised by Danske Bank A S

Danske Bank A S raised its stake in Labcorp Holdings Inc. (NYSE:LH) by 17.1% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 41,602 shares of the medical research company’s stock after buying an additional 6,080 shares during the quarter. Danske Bank A S’s holdings in Labcorp were worth $10,437,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in LH. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Labcorp during the fourth quarter valued at approximately $26,000. JPL Wealth Management LLC bought a new stake in shares of Labcorp during the third quarter valued at approximately $28,000. Eagle Bay Advisors LLC bought a new stake in shares of Labcorp during the fourth quarter valued at approximately $29,000. Motco bought a new stake in shares of Labcorp during the third quarter valued at approximately $32,000. Finally, Beacon Financial Strategies CORP bought a new stake in shares of Labcorp during the fourth quarter valued at approximately $33,000. 95.94% of the stock is currently owned by institutional investors.

Labcorp Price Performance

Shares of NYSE:LH opened at $252.99 on Tuesday. Labcorp Holdings Inc. has a 12 month low of $239.67 and a 12 month high of $293.72. The stock has a market cap of $20.79 billion, a price-to-earnings ratio of 22.41, a PEG ratio of 1.72 and a beta of 0.91. The stock’s 50 day moving average price is $270.69 and its 200 day moving average price is $267.33. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54.

Labcorp (NYSE:LH) last announced its earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping the consensus estimate of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter in the previous year, the company earned $3.84 earnings per share. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Equities research analysts anticipate that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be given a $0.72 dividend. The ex-dividend date is Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp’s payout ratio is 25.51%.

Analyst Ratings Changes

A number of research firms have recently weighed in on LH. Evercore reaffirmed an “outperform” rating and set a $300.00 price target on shares of Labcorp in a report on Wednesday, April 8th. Piper Sandler lifted their price objective on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, February 24th. Morgan Stanley restated an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Robert W. Baird set a $334.00 price objective on shares of Labcorp in a research note on Friday. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $308.00.

Insider Buying and Selling at Labcorp

In other Labcorp news, EVP Der Vaart Sandra D. Van sold 548 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $284.91, for a total value of $156,130.68. Following the sale, the executive vice president directly owned 2,579 shares in the company, valued at approximately $734,782.89. The trade was a 17.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jonathan C. Meltzer sold 87 shares of the company’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the completion of the transaction, the executive vice president directly owned 2,782 shares in the company, valued at $807,948.44. This represents a 3.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,113 shares of company stock valued at $4,547,450 in the last ninety days. 0.84% of the stock is owned by insiders.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.